Harvard Pilgrim Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication (FDA-approved for adults with established CVD who are overweight or obese) with prior authorization
Certain medical issues require additional caution
In the triple therapy cohort receiving metformin, SGLT2-i, and GLP-1RA, overbasalization declined from 62.5 to 17.5%, and 42.5% of patients were able to stop insulin entirely, reinforcing the additive benefits of combination therapy [44]
Despite not being a primary aim of the study, by collecting participant characteristics we saw clinically significant improvements in physical health (weight and HbA1c), of similar magnitude to that seen in trials of GLP-1 receptor agonists in obesity [35] and T2D and overweight [36, 37]
Theyre still classified as diabetes and weight-loss medications, so doctors dont prescribe them off-label for substance use disorders
Unexplained or debilitating fatigue